Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers

Overview

This is a phase 2 double-blind clinical study to evaluate the efficacy and Safety of ALLO-ASC-SHEET in subjects with Diabetic Foot Ulcers, compared to placebo therapy.

Full Title of Study: “A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: December 2019

Detailed Description

1. Active Group: ALLO-ASC-SHEET

2. Control Group: Hydrogel SHEET (vehicle control)

3. Study Type: Interventional

4. Study Design: Randomized, Comparator-controlled, Double-blind, multi-center study.

Interventions

  • Biological: ALLO-ASC-DFU
    • Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer
  • Procedure: Hydrogel SHEET(Vehicle control)
    • Application of Hydrogel SHEET to diabetic foot ulcer

Arms, Groups and Cohorts

  • Experimental: ALLO-ASC-DFU
    • Experimental: ALLO-ASC-DFU Hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells
  • Placebo Comparator: Hydrogel SHEET(Vehicle control)
    • Placebo Comparator: Vehicle Control Hydrogel sheet without allogenic adipose-derived mesenchymal stem cells

Clinical Trial Outcome Measures

Primary Measures

  • Proportions of subjects who achieved complete wound closure
    • Time Frame: During 12 weeks

Secondary Measures

  • Time to initial complete wound closure between the two groups
    • Time Frame: During 12 weeks
  • Changes in wound size compared to baseline between the two groups
    • Time Frame: During 12 weeks
    • Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices)
  • Proportions of subjects who achieved complete wound closure by the classification of location of diabetic foot ulcer, Plantar and the other location between the two groups
    • Time Frame: During 12 weeks(at every visit during treatment period)
  • Durability of complete wound closure
    • Time Frame: Follow up to 24 weeks from the initial complete wound closure.
    • Wound size is measured by using eKare 3D Wound Measurement system(Mobile Devices)

Participating in This Clinical Trial

Inclusion Criteria

1. Male or female subjects between 18 and 80 years of age.

2. Diagnosed with Type I or Type II diabetics and has diabetic foot ulcers for longer than 4 weeks at the screening visit.

3. Foot ulcer located in the instep, border or sole of the foot, with ulcer size between 1 cm2 and 15 cm2.

4. Ulcer graded I by Wagner grade, and extended to skin, subcutaneous tissue, but without exposure of muscle, tendon, bone or joint capsule.

5. Ulcer is free of necrotic debris, exhibits no signs of clinical infection.

6. Ulcer area blood circulation meets one of the following criteria

  • A. Blood vessels around the ulcer detected by Doppler Test
  • B. range of Ankle Brachial Index(ABI) was > 0.7 to < 1.3
  • C. Transcutaneous oxygen pressure, (TcPO2) > 30 mmHg.

7. Is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria

1. Ulcer is of non-diabetic pathophysiology.

2. The ulcer has increased or decreased in size by ≥ 30% during the week after the Screening Visit.

3. Is Human Immunodeficiency Virus (HIV) positive?

4. Have severe hepatic deficiencies.

5. Have a glycated hemoglobin A1c (HbA1c) level of > 10%.

6. Have allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue.

7. Require intravenous (IV) antibiotics to treat the target wound infection.

8. Have severe renal failure including subject on renal dialysis.

9. Pregnant or breast-feeding.

10. Is unwilling to use an "effective" method of contraception during the study.

11. Have evidence of current infection including pus drainage from the wound site.

12. Have a clinically relevant history of alcohol or drugs abuse.

13. Have postprandial blood sugar > 350 mg/dl.

14. Is not able to understand the objective of this study or to comply with the study requirements.

15. Is considered by the investigator to have a significant disease which might have impacted the study.

16. Is considered not suitable for the study by investigator.

17. Have a history of malignancy within the last five years (except basal cell carcinoam in situ).

18. Is currently or were enrolled in another clinical study within 60 days of screening.

19. Have undergone wound treatments with growth factors, dermal substitutes, or other biological therapies within the last 30 days.

20. Is receiving oral or parenteral corticosteroids, immunosuppressive, or cytotoxic agents with unstable dose prior to 4 weeks from screening.

21. Cannot maintain off-loading process

22. Panel reactive antibody (PRA) levels ≥ 20%

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Anterogen Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David G. Armstrong, MD.Ph D., Principal Investigator, University of Southern California
    • Alexander M. Reyzelman, DPM, Principal Investigator, Center for Clinical Research
    • Young Nathan, DPM, Principal Investigator, Martinsville Research Institute
  • Overall Contact(s)
    • David G. Armstrong, MD.Ph D., (+1)5203059393, armstrong@usa.net

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.